文献速递基础与转化研究新药、器械与细胞基因治疗研发

ASCT2谷氨酰胺转运的药理阻断在临床前模型中显示抗肿瘤疗效

Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacy in preclinical models.
PubMed 文献 · Nat Med · 2018-01-15

本研究报道了V-9302的临床前开发,V-9302是跨膜谷氨酰胺通量的竞争性小分子拮抗剂,选择性且强效靶向氨基酸转运体ASCT2。用V-9302药理阻断ASCT2导致癌细胞生长和增殖减弱、细胞死亡增加、氧化应激增加,这些共同促成了体外和体内的抗肿瘤反应。据作者所知,这是首个证明谷氨酰胺转运药理抑制剂在肿瘤学中效用的研究。

要点

  • V-9302是靶向ASCT2的竞争性小分子拮抗剂,选择性且强效阻断谷氨酰胺转运。
  • 药理阻断ASCT2导致癌细胞生长增殖减弱、细胞死亡增加、氧化应激增加。
  • 体外和体内抗肿瘤反应共同由上述细胞效应促成。

核心结论

  • V-9302药理阻断ASCT2依赖的谷氨酰胺转运在临床前模型中产生抗肿瘤疗效。
  • 据作者所知,这是首个证明谷氨酰胺转运药理抑制剂在肿瘤学中效用的研究。

研究设计与样本

  • 临床前开发研究,报道V-9302作为跨膜谷氨酰胺通量的竞争性小分子拮抗剂。

主要发现

  • 用V-9302药理阻断ASCT2导致癌细胞生长和增殖减弱、细胞死亡增加、氧化应激增加。
  • 上述效应共同促成了体外和体内的抗肿瘤反应。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The unique metabolic demands of cancer cells underscore potentially fruitful opportunities for drug discovery in the era of precision medicine. However, therapeutic targeting of cancer metabolism has led to surprisingly few new drugs to date. The neutral amino acid glutamine serves as a key intermediate in numerous metabolic processes leveraged by cancer cells, including biosynthesis, cell signaling, and oxidative protection. Herein we report the preclinical development of V-9302, a competitive small molecule antagonist of transmembrane glutamine flux that selectively and potently targets the amino acid transporter ASCT2. Pharmacological blockade of ASCT2 with V-9302 resulted in attenuated cancer cell growth and proliferation, increased cell death, and increased oxidative stress, which collectively contributed to antitumor responses in vitro and in vivo. This is the first study, to our knowledge, to demonstrate the utility of a pharmacological inhibitor of glutamine transport in oncology, representing a new class of targeted therapy and laying a framework for paradigm-shifting therapies targeting cancer cell metabolism.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Schulte ML, Fu A, Zhao P, et al. Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacy in preclinical models. Nat Med. 2018. PMID: 29334372. doi:10.1038/nm.4464

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。